Eli Lilly's Strategic Acquisition of Verve Therapeutics

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing therapies for cardiovascular diseases, in a deal valued at up to $1.3 billion. The agreement includes an upfront payment of approximately $1 billion, offering $10.50 per share—a 113% premium over Verve's 30-day average stock price. Additionally, shareholders may receive up to $3.00 per share through a non-tradeable contingent value right (CVR), contingent upon the advancement of Verve's lead therapy, VERVE-102, into a Phase 3 clinical trial within ten years .

VERVE-102 is an innovative in vivo gene-editing therapy targeting the PCSK9 gene, which plays a crucial role in regulating cholesterol levels. Currently in Phase 1b clinical trials, the therapy has received Fast Track designation from the U.S. Food and Drug Administration. Early trial results have demonstrated significant reductions in LDL cholesterol levels, with some patients experiencing up to a 69% decrease .

This acquisition aligns with Eli Lilly's strategic focus on expanding its portfolio into genetic medicines and addressing cardiovascular health. By integrating Verve's pioneering gene-editing platform, Lilly aims to transform the treatment paradigm for cardiovascular disease from chronic management to a potential one-time intervention .

The transaction is expected to close in the third quarter of 2025, pending customary closing conditions, including the tender of a majority of Verve's outstanding shares. Verve's board of directors has unanimously recommended that shareholders tender their shares in the offer .